The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT04632862

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04632862
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04632862. Randomized; double masking; primary purpose treatment. Start 2020-11-11 (actual); primary completion 2021-11-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
DWP16001
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct04632862
Content hash
e6f138c1727ef381c97953644a7f416163ac4fadce8f3ad9e4402fb1df8f38ca